Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

3/7/24 4:05:00 PM ET

Medical/Dental Instruments

Health Care

Get the next $QNRX alert in real time by email

ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.

The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024. The call will include a discussion of fourth quarter and 2023 financial results and a corporate update.

The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international).

The live and archived webcast of the call will also be available on the Quoin Pharmaceuticals website under the Investors section or by following this link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZmehVyN5

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:

Investor Relations

PCG Advisory

Stephanie Prince

[email protected]

(646) 863-6341

Get the next $QNRX alert in real time by email

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Chat with this insight

Recent Analyst Ratings for
$QNRX

$QNRX
Press Releases

Fastest customizable press release news feed in the world

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

$QNRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

$QNRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

$QNRX
Financials

Live finance-specific insights

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

$QNRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

$QNRX
SEC Filings

Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Chat with this insight

Recent Analyst Ratings for $QNRX

$QNRX Press Releases

Fastest customizable press release news feed in the world

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

$QNRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

$QNRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

$QNRX Financials

Live finance-specific insights

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

$QNRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

$QNRX SEC Filings

Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Recent Analyst Ratings for
$QNRX

$QNRX
Press Releases

$QNRX
Insider Trading

$QNRX
Insider Purchases

$QNRX
Financials

$QNRX
Large Ownership Changes

$QNRX
SEC Filings